Accelera provides support services and consultancy to develop both New Chemical Entities (NCEs) and biologics as new oncology drugs through Accelera Oncology, a dedicated team of experts in preclinical tumor models, PK/PD, Attrition Reducing Technologies (ART), Drug Safety, Bioanalysis and Regulatory Development.

Accelera Oncology represents a unique combination of product development experience from cytotoxics to molecular targeted therapeutics, gained through time as an R&D site of major pharmaceutical companies (Pharmacia, Pfizer), and in collaboration with the leading clinical oncology centers in Europe and the USA.

Accelera Oncology’s experts are available to assess the status of your oncology program, and to provide advice and input to optimize drug development strategies.